References

W
Wyles D, Bräu N, Kottilil S, et al. Sofosbuvir and Velpatasvir for the Treatment of HCV in Patients Coinfected with HIV-1: an Open-Label, Phase 3 Study. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2017.
Wyles DL, Pockros P, Morelli G, et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology. 2015;61(6):1793-1797.
Wyles D, Poordad F, Wang S. Surveyor-II, Part 3: Efficacy and Safety of Glecaprevir/Pibrentasvir (Abt-493/Abt-530) in Patients with Hepatitis C Virus Genotype 3 Infection with Prior Treatment Experience and/or Cirrhosis. [Abstract 113]. In: AASLD. AASLD.; 2016.
Wyles DL, Brau N, Kottilil S, et al. Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study Abstract PS104. In: International Liver Congress 2016. April 13-17. International Liver Congress 2016. April 13-17. Barcelona, Spain; 2016.
Wyles D, Mangia A, Cheng W, et al. Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir [Epub ahead of print]. Antiviral Therapy. 2017.
Wyles DL, Dvory-Sobol H. Wyles and Dvory-Sobol in press 2016. 2016.
Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):714-725.
Y
Yeh WW. oral presentation International Workshop on Clinical Pharmacology of HIV and Hepatitis
Therapy
. 2015.
Yoneda M, Saito S, Ikeda T, et al. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients. J Viral Hepat. 2007;14(9):600-607.
Yoshida EM, Kwo P, Agarwal K, et al. Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. Annals of Hepatology. 2017;16(3):375 - 381.
Younossi ZM, Jiang Y, Smith NJ, Stepanova M, Beckerman R. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States. Hepatology. 2015;61(5):1471-1478.
Younossi ZM, Stepanova M, Nader F, et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology. 2014;59(6):2161-2169.
Younossi ZM, Bacon B, Dieterich D, Flamm SL, et al. Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network. J Viral Hepat. 2016;23(6):447-54.
Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2013;[Epub ahead of print].
Younossi ZM, Stepanova M, Afdhal NH, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015;63(2):337-345.
Younossi ZM, Stepanova M, Henry L, Nader F, Hunt S. An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens. The American Journal of Gastroenterology. 2016;111(6):808 - 816.
Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment. Pharmacol. Ther. 2015;41(6):544-563.
Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. Journal of Hepatology. 2016;65(1):33 - 39.
Younossi ZM, Stepanova M, Sulkowski MS, et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes. J Infect Dis. 2015;212(3):367-377.
Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. 2007;56(4):553-559.
Top